2024-10-18 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis Report

**1. Performance Comparison & Divergence:**

Gilead Sciences Inc. (GILD) has underperformed significantly compared to the S&P 500 (VOO) over the given period. The cumulative return for GILD is -10.38%, while VOO's return is 136.93%. This leads to a substantial divergence of -147.31, placing GILD at the 5.35% percentile of historical divergence values. 

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company specializing in the development and commercialization of antiviral drugs, oncology treatments, and inflammatory diseases therapies.

**2. Recent Price Movement:**

* **Closing Price:** $86.75
* **5-Day Moving Average:** $85.52
* **20-Day Moving Average:** $84.50
* **60-Day Moving Average:** $79.76

The stock is currently trading above all three moving averages, suggesting a potential upward trend.

**3. Technical Indicators & Expected Return:**

* **RSI:** 72.16 - The RSI is currently in the overbought territory, suggesting potential for a correction.
* **PPO:** -0.11 - The negative PPO indicates a bearish trend, but it is relatively close to zero, suggesting potential for a rebound.
* **Delta_Previous_Relative_Divergence:** -3.06 - This indicates a recent short-term downtrend in relative performance. 
* **Expected Return:** 0.0% - The expected return is 0% over the next 5 years, based on the current market conditions and historical performance.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report, released on 2024-08-08, showed an EPS of 1.29 and revenue of $6.95 billion, exceeding analysts' expectations of $1.18 EPS and $6.87 billion revenue. This positive earnings surprise could be a catalyst for stock price appreciation.

**5. News & Recent Issues:**

Recent market sentiment towards Gilead Sciences has been relatively positive. Analysts are generally optimistic about the company's long-term growth potential, particularly with the strong performance of its antiviral drugs and promising pipeline of new therapies. Some recent highlights include:

* **Strong Q2 2024 Earnings:** Gilead exceeded analyst expectations, demonstrating strong revenue growth and profitability.
* **Focus on Innovation:** The company is actively developing new therapies in areas like oncology and immunology, positioning itself for future growth.
* **Continued Success of Key Products:** Gilead's flagship antiviral drugs continue to perform well, driving consistent revenue streams. 

**6. Summary:**

Gilead Sciences has underperformed the market significantly in the past, but its recent earnings beat and positive market sentiment suggest potential for a rebound. While the stock's RSI indicates overbought conditions and the PPO is slightly bearish, the company's strong financial performance and focus on innovation could lead to future growth.

**7. Conclusion:**

Gilead Sciences presents a mixed picture. While its past performance has been disappointing compared to the market, the company has demonstrated positive momentum in recent quarters. Investors looking for growth potential may consider Gilead as a long-term investment, but caution should be exercised due to the current overbought technical indicators and the potential for short-term correction. Further analysis of the company's pipeline, market competition, and regulatory environment is necessary for informed decision-making. 
